Enhanced cytotoxic effect of camptothecin nanosponges in anaplastic thyroid cancer cells in vitro and in vivo on orthotopic xenograft tumors. (1st January 2017)
- Record Type:
- Journal Article
- Title:
- Enhanced cytotoxic effect of camptothecin nanosponges in anaplastic thyroid cancer cells in vitro and in vivo on orthotopic xenograft tumors. (1st January 2017)
- Main Title:
- Enhanced cytotoxic effect of camptothecin nanosponges in anaplastic thyroid cancer cells in vitro and in vivo on orthotopic xenograft tumors
- Authors:
- Gigliotti, Casimiro Luca
Ferrara, Benedetta
Occhipinti, Sergio
Boggio, Elena
Barrera, Giuseppina
Pizzimenti, Stefania
Giovarelli, Mirella
Fantozzi, Roberto
Chiocchetti, Annalisa
Argenziano, Monica
Clemente, Nausicaa
Trotta, Francesco
Marchiò, Caterina
Annaratone, Laura
Boldorini, Renzo
Dianzani, Umberto
Cavalli, Roberta
Dianzani, Chiara - Abstract:
- Abstract: Anaplastic carcinoma of the thyroid (ATC) is a lethal human malignant cancer with median survival of 6 months. To date, no treatment has substantially changed its course, which makes urgent need for the development of novel drugs or novel formulations for drug delivery. Nanomedicine has enormous potential to improve the accuracy of cancer therapy by enhancing availability and stability, decreasing effective doses and reducing side effects of drugs. Camptothecin (CPT) is an inhibitor of DNA topoisomerase-I with several anticancer properties but has poor solubility and a high degradation rate. Previously, we reported that CPT encapsulated in β-cyclodextrin-nanosponges (CN-CPT) increased solubility, was protected from degradation and inhibited the growth of prostate tumor cells both in vitro and in vivo . The aim of this study was to extend that work by assessing the CN-CPT effectiveness on ATC both in vitro and in vivo . Results showed that CN-CPT significantly inhibited viability, clonogenic capacity and cell-cycle progression of ATC cell lines showing a faster and enhanced effect compared to free CPT. Moreover, CN-CPT inhibited tumor cell adhesion to vascular endothelial cells, migration, secretion of pro-angiogenic factors (IL-8 and VEGF-α), expression of β-PIX, belonging to the Rho family activators, and phosphorylation of the Erk1/2 MAPK. Finally, CN-CPT significantly inhibited the growth, the metastatization and the vascularization of orthotopic ATC xenograftsAbstract: Anaplastic carcinoma of the thyroid (ATC) is a lethal human malignant cancer with median survival of 6 months. To date, no treatment has substantially changed its course, which makes urgent need for the development of novel drugs or novel formulations for drug delivery. Nanomedicine has enormous potential to improve the accuracy of cancer therapy by enhancing availability and stability, decreasing effective doses and reducing side effects of drugs. Camptothecin (CPT) is an inhibitor of DNA topoisomerase-I with several anticancer properties but has poor solubility and a high degradation rate. Previously, we reported that CPT encapsulated in β-cyclodextrin-nanosponges (CN-CPT) increased solubility, was protected from degradation and inhibited the growth of prostate tumor cells both in vitro and in vivo . The aim of this study was to extend that work by assessing the CN-CPT effectiveness on ATC both in vitro and in vivo . Results showed that CN-CPT significantly inhibited viability, clonogenic capacity and cell-cycle progression of ATC cell lines showing a faster and enhanced effect compared to free CPT. Moreover, CN-CPT inhibited tumor cell adhesion to vascular endothelial cells, migration, secretion of pro-angiogenic factors (IL-8 and VEGF-α), expression of β-PIX, belonging to the Rho family activators, and phosphorylation of the Erk1/2 MAPK. Finally, CN-CPT significantly inhibited the growth, the metastatization and the vascularization of orthotopic ATC xenografts in SCID/beige mice without apparent toxic effects in vivo . This work extends the previous insight showing that β-cyclodextrin-nanosponges are a promising tool for the treatment of ATC. … (more)
- Is Part Of:
- Drug delivery. Volume 24:Number 1(2017)
- Journal:
- Drug delivery
- Issue:
- Volume 24:Number 1(2017)
- Issue Display:
- Volume 24, Issue 1 (2017)
- Year:
- 2017
- Volume:
- 24
- Issue:
- 1
- Issue Sort Value:
- 2017-0024-0001-0000
- Page Start:
- 670
- Page End:
- 680
- Publication Date:
- 2017-01-01
- Subjects:
- Camptothecin -- β-cyclodextrin-nanosponges -- anaplastic thyroid carcinoma -- cell migration -- cell adhesion
Drug delivery systems -- Periodicals
Drug targeting -- Periodicals
615.05 - Journal URLs:
- http://informahealthcare.com/loi/drd ↗
http://informahealthcare.com ↗ - DOI:
- 10.1080/10717544.2017.1303856 ↗
- Languages:
- English
- ISSNs:
- 1071-7544
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3629.104600
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 25103.xml